Tongri Liu | Chief Representative
Allife Medicine

Tongri Liu, Chief Representative, Allife Medicine

Tongri Liu (Tony) has completed his Ph.D. at the age of 27 years from University of Oxford, UK. He is now the chief overseas representative of Beijing ALLIFE Medicine Science and Technology Co. Ltd., a Chinese Pharmaceutical Company specialised in iPSc derived cell and gene therapies, and the director of ALLIFE Medicine UK branch company and the UK subsediary company, iCell Therapeutics Ltd.. He has helped established the UK companies and is leading the clinical trial application with the MHRA in the UK for both iPSc-EPC and iPSc-Islet projects.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 17:40

In Pursuit of the First Clinical Trial for a Chinese iPSc Derived ATMP (iPSc-Endothelial Progenitor Cell) in the UK

  • Manufacturing protocols and QC standards for iPSc-EPC have been developed in Allife Medicine.
  • Pre-clinical studies have shown positive effects on neuron re-myelination in rats and that iPSc-EPC is able to trigger endothelium lesion recovery in nude mice, with little safety concern in Toxicity and Tumorigenesis.
  • A Phase I/IIα clinical trial to use autologous iPSc-EPC for Ischemic Stroke is planned to start in early 2021.
last published: 04/Jun/20 08:25 GMT

back to speakers